A game-changing cancer breakthrough is gaining momentum, with major FDA designations, groundbreaking clinical results, and a pivotal study expansion on the horizon.

But despite these milestones, short sellers are betting against it—creating what could be a massive short squeeze opportunity.

Did they think we wouldn’t notice?

🚀 Read the Full Report Before the Market Wakes Up! 🚀

What’s the Breakthrough?

Most cancer treatments brutalize the body in an attempt to kill tumors. This one works smarter.

This cutting-edge therapy unleashes a naturally occurring virus that infiltrates tumors and trains the immune system to recognize and destroy cancer cells—something tumors usually trick the body into ignoring. Unlike chemotherapy, which wipes out everything in its path, this method targets cancer directly, making the disease more vulnerable to attack while keeping healthy cells safe.

It has already doubled survival rates in key trials, secured two FDA Fast Track designations, and is now on the verge of a pivotal trial expansion.

The science is real. The opportunity is massive.

Why Is This a Potential Short Squeeze?

✅ Two FDA Fast Track designations for high-need cancer treatments
✅ Final-stage clearance for a pivotal trial expansion—a major catalyst ahead
✅ Undervalued stock with strong clinical success—but heavily shorted
✅ A big move could force shorts to cover fast—triggering a breakout

With the right catalyst, this stock could explode upward—and smart investors are watching closely.

🚀 Click Here to Read the Full Report Before the Market Wakes Up! 🚀